1.中国中医科学院中医临床基础医学研究所,北京市东城区东直门内南小街16号,100700
2.中国中医科学院广安门医院
3.北京中医药大学
geyouwen@126.com,(010)64064411
收稿:2021-06-08,
修回:2021-08-20,
纸质出版:2021-10-17
移动端阅览
王晶亚,李慧珍,郭玉娜等.清肺排毒汤联合西医常规疗法治疗老年新型冠状病毒肺炎157例临床疗效回顾性研究[J].中医杂志,2021,62(20):1788-1794.
WANG Jingya,LI Huizhen,GUO Yuna,et al.Qingfei Paidu Decoction (清肺排毒汤) Combined with Western Routine Treatment for Elderly Patients with Coronavirus Disease 2019: A Retrospective Study[J].Journal of Traditional Chinese Medicine,2021,62(20):1788-1794.
王晶亚,李慧珍,郭玉娜等.清肺排毒汤联合西医常规疗法治疗老年新型冠状病毒肺炎157例临床疗效回顾性研究[J].中医杂志,2021,62(20):1788-1794. DOI: 10.13288/j.11-2166/r.2021.20.008.
WANG Jingya,LI Huizhen,GUO Yuna,et al.Qingfei Paidu Decoction (清肺排毒汤) Combined with Western Routine Treatment for Elderly Patients with Coronavirus Disease 2019: A Retrospective Study[J].Journal of Traditional Chinese Medicine,2021,62(20):1788-1794. DOI: 10.13288/j.11-2166/r.2021.20.008.
目的
2
回顾性分析清肺排毒汤联合西医常规治疗老年新型冠状病毒肺炎(新冠肺炎)的临床疗效。
方法
2
回顾性收集2020年1月21日至3月18日9个省(直辖市)36家医院确诊的老年新冠肺炎病例,并根据临床分型分为重型组(包括重型和危重型)和非重型组(包括轻型和普通型)进一步分层探讨。描述患者的一般资料,对比分析患者服用清肺排毒汤治疗前及治疗3天、6天后临床症状(包括发热、咳嗽、乏力、厌食、气喘),实验室指标变化(包括白细胞计数、中性粒细胞计数、淋巴细胞计数、丙氨酸氨基转氨酶、门冬氨酸氨基转氨酶、肌酐、尿素氮、乳酸脱氢酶、降钙素、C反应蛋白),肺部病灶吸收情况。记录患者治疗转归情况及核酸转阴时间、住院时间及不良事件发生情况。
结果
2
共纳入157例老年新冠肺炎病例,其中非重型组131例(83.4%),重型组26例(16.6%)。与治疗前比较,清肺排毒汤联合西医常规治疗3天、6天后发热、咳嗽、乏力、气喘症状人数减少(
P
<0.05或
P
<0.01);患者完全退热时间为1.0(1.0,3.0)天,气喘缓解时间为1.0(1.0,4.0)天,重型组与非重型组患者完全退热时间和气喘缓解时间比较差异有统计学意义(
P
<0.05)。与治疗前比较,157例患者治疗6天后淋巴细胞计数、乳酸脱氢酶及C反应蛋白改善明显(
P
<0.05)。治疗6天后,共获得肺部CT影像学资料完整患者114例,其中94例患者肺部病灶呈现不同程度的吸收,吸收率为82.5%。155例患者痊愈出院,2例重症患者死亡,痊愈患者第一次核酸转阴中位时间为11.0(3.0,16.0)天,平均住院时间为19.0(6.0,23.0)天。痊愈患者治疗期间均未发生严重不良事件。
结论
2
清肺排毒汤联合西医常规疗法可改善老年新冠肺炎患者的临床症状,改善炎症指标,促进肺部病灶的吸收,改善预后,且安全性好。
Objective
2
To explore the clinical effects of
Qingfei Paidu Decoction
(清肺排毒汤) combined with western routine treatment for elderly patients with coronavirus disease 2019 (COVID-19).
Methods
2
Clinical data of elderly COVID-19 patients were retrospectively collected from 36 hospitals in 9 provinces (municipalities) from January 21 to March 18, 2020. Patients were classified into severe group (severe and critically ill cases) and non-severe group (mild and moderate cases) for further analyses. Data on the general information, clinical symptoms including fever, cough, fatigue, anorexia and asthma, laboratory indexes including white blood cell count, neutrophil count, lymphocyte count, alanine aminotransferase, aspartate aminotransferase, creatinine, urea nitrogen, lactate dehydrogenase, calcitonin and C-reactive protein, and absorption of lung lesions were assessed and compared between baseline and three days as well as six days after treatment. The time to negative conversion of nucleic acid test result and hospitalization duration were calculated, and adverse events were recorded.
Results
2
A total of 157 elderly COVID-19 cases were included, with 131 (83.4%) patients in the non-severe group and 26 patients (16.6%) in the severe group. Compared to those before treatment of
Qingfei Paidu Decoction
and
routine therapy, the number of patients with fever, cough, fatigue and asthma after 3-day and 6-day treatment significantly decreased (
P
<0.05 or
P
<0.01). The time to relief of fever was 1.0 (1.0, 3.0) day, and that of asthma was 1.0 (1.0, 4.0) day; there were significant differences between severe and non-severe group in the relief time of fever and asthma (
P
<0.05). After six days of treatment, the lymphocyte count, lactate dehydrogenase and C-reactive protein were significantly improved (
P
<0.05); different degrees of absorption were seen in 94 out of 114 (82.5%) patients whose lung imaging results were available. Of the 157 patients, 155 were cured and discharged, while two severe patients died; for discharged patients, the median time to first negative conversion of nucleic acid test result was 11.0 (3.0, 16.0) days, and the average hospitalization duration was 19.0 (6.0, 23.0) days. No serious adverse events occurred.
Conclusion
2
Qingfei Paidu Decoction
combined with western routine treatment can improve clinical symptoms of elderly COVID-19 patients, improve inflammation indicators, promote the absorption of lung lesions, improve prognosis, and is consi-dered to be safe.
LU RJ , ZHAO X , LI J , et al . Genomic characterisation and epidemiology of 2019 novel coronavirus:implications for virus origins and receptor binding [J]. Lancet , 2020 , 395 ( 10224 ): 565 - 574 .
国家中医药管理局 . 中医药有效方剂筛选研究取得阶段性进展:试点省份临床观察显示:清肺排毒汤治疗总有效率可达90%以上 [EB/OL].( 2020-02-06 )[ 2021-06-08 ]. http://bgs.satcm.gov.cn/gongzuodongtai/2020-02-06/12866.html http://bgs.satcm.gov.cn/gongzuodongtai/2020-02-06/12866.html .
国家卫生健康委员会 , 国家中医药管理局 . 关于推荐在中西医结合救治新型冠状病毒感染的肺炎中使用“清肺排毒汤”的通知 [EB/OL].( 2020-02-07 )[ 2021-06-08 ]. http://yzs.satcm.gov.cn/zhengcewenjian/2020-02-07/12876.html http://yzs.satcm.gov.cn/zhengcewenjian/2020-02-07/12876.html .
中华人民共和国国家卫生健康委员会 . 关于做好老年人新型冠状病毒感染肺炎疫情防控工作的通知 [EB/OL].( 2020-01-28 )[ 2021-06-08 ]. http://www.gov.cn/xinwen/2020-01/28/content_5472793.htm http://www.gov.cn/xinwen/2020-01/28/content_5472793.htm .
国家卫生健康委办公厅 , 国家中医药管理局办公室 . 关于印发新型冠状病毒肺炎诊疗方案(试行第三版)的通知 [EB/OL].( 2020-01-23 )[ 2021-06-08 ]. http://www.gov.cn/zhengce/zhengceku/2020-01/23/content_5471832.htm http://www.gov.cn/zhengce/zhengceku/2020-01/23/content_5471832.htm .
国家卫生健康委办公厅 , 国家中医药管理局办公室 . 关于印发新型冠状病毒肺炎诊疗方案(试行第四版)的通知 [EB/OL].( 2020-01-28 )[ 2021-06-08 ]. http://www.gov.cn/zhengce/zhengceku/2020-01/28/content_5472673.htm http://www.gov.cn/zhengce/zhengceku/2020-01/28/content_5472673.htm .
国家卫生健康委办公厅 , 国家中医药管理局办公室 . 关于印发新型冠状病毒肺炎诊疗方案(试行第五版)的通知 [EB/OL].( 2020-02-05 )[ 2021-06-08 ]. http://www.gov.cn/zhengce/zhengceku/2020-02/05/content_5474791.htm http://www.gov.cn/zhengce/zhengceku/2020-02/05/content_5474791.htm .
国家卫生健康委办公厅 , 国家中医药管理局办公室 . 关于印发新型冠状病毒肺炎诊疗方案(试行第六版)的通知 [EB/OL].( 2020-02-19 )[ 2021-06-08 ]. http://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5480948.htm http://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5480948.htm .
国家卫生健康委办公厅 , 国家中医药管理局办公室 . 关于印发新型冠状病毒肺炎诊疗方案(试行第七版)的通知 [EB/OL].( 2020-03-04 )[ 2021-06-08 ]. http://www.gov.cn/zhengce/zhengceku/2020-03/04/content_5486705.htm http://www.gov.cn/zhengce/zhengceku/2020-03/04/content_5486705.htm .
ZHOU F , YU T , DU R , et al . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [J]. Lancet , 2020 , 395 ( 10229 ): 1054 - 1062 .
龚惠莉 , 黄汉平 , 周霞 , 等 . 新型冠状病毒核酸转阴时间相关因素及其对预后的影响 [J]. 医药导报 , 2020 , 39 ( 6 ): 811 - 814 .
范逸品 , 王燕平 , 张华敏 , 等 . 试析从寒疫论治新型冠状病毒肺炎 [J]. 中医杂志 , 2020 , 61 ( 5 ): 369 - 374 .
谢鸣 . 对中医药防治新型冠状病毒肺炎清肺排毒汤制方及运用的思考 [J]. 中医杂志 , 2020 , 61 ( 13 ): 1105 - 1109 .
薛伯寿 , 姚魁武 , 薛燕星 , 等 . “清肺排毒汤”快速有效治疗新型冠状病毒肺炎的中医理论分析 [J]. 中医杂志 , 2020 , 61 ( 6 ): 461 - 462 .
WU Z , MCGOOGAN JM . Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention [J]. JAMA , 2020 , 323 ( 13 ): 1239 - 1242 .
SONG J , HU W , YU Y , et al . A comparison of clinical characteristics and outcomes in elderly and younger patients with COVID-19 [J]. Med Sci Monit , 2020 , 26 : e925047 . doi: 10.12659/MSM.925047 http://dx.doi.org/10.12659/MSM.925047 .
ZOU X , CHEN K , ZOU J , et al . Single-cell RNA-seqdata analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection [J]. Front Med , 2020 , 14 ( 2 ): 185 - 192 .
HUANG H , CAI SJ , LI YP , et al . Prognostic factors for COVID-19 pneumonia progression to severe symptoms based on the earlier clinical fearures:a retrospective analysis [J]. Front Med (Lausanne) , 2020 , 7 : 557453 . doi: 10.3389/fmed.2020.557453 http://dx.doi.org/10.3389/fmed.2020.557453 .
姚佳 , 史晓燕 , 陈秋 , 等 . 清肺排毒汤治疗新型冠状病毒肺炎的方药理论研究 [J]. 辽宁中医杂志 , 2020 , 47 ( 5 ): 94 - 98 .
李春波 , 苏韫 , 刘永琦 , 等 . 清肺排毒汤治疗新型冠状病毒肺炎的中医理论及现代药理学机制 [J]. 中医杂志 , 2020 , 61 ( 15 ): 1299 - 1302 .
XIN SY , CHENG XQ , ZHU B , et al . Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment [J]. Biomed Pharmacother , 2020 : 129 . doi: 10.1016/j.biopha.2020.110500 http://dx.doi.org/10.1016/j.biopha.2020.110500 .
ZHANG LH , ZHENG X , BAI XK , et al . Association between use of Qingfei Paidu Tang and mortality in hospitalized patients with COVID-19: a national retrospective registry study [J]. Phytomedicine , 2021 , 85 : 153531 . doi: 10.1016/j.phymed.2021.153531 http://dx.doi.org/10.1016/j.phymed.2021.153531 .
王谷宜 , 吴晨方 , 张权 , 等 . 2019冠状病毒病老年患者的临床特点及重症的危险因素 [J]. 中南大学学报(医学版) , 2020 , 45 ( 5 ): 542 - 548 .
LI Q , GUAN XH , WU P , et al . Early transmission dynamics in Wuhan, China,of novel coronavirus-infected pneumonia [J]. N Engl J Med , 2020 , 382 ( 13 ): 1199 - 1207 .
ZHAVORONKOV A . Geroprotective and senoremediative strategies to reduce the comorbidity,infection rates,severity,and lethality in gerophilic and gerolavic infections [J]. Aging(Albany NY) , 2020 , 12 ( 8 ): 6492 - 6510 .
ZHANG W , HOU W , JIN RH , et al . Clinical characteristics and outcomes in elderly with coronavirus disease 2019 in Beijing, China: a retrospective cohort study [J]. Intern Emerg Med , 2021 , 16 ( 4 ): 875 - 882 .
WANG L , HE WB , YU X , et al . Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up [J]. J Infect , 2020 , 80 ( 6 ): 639 - 645 .
0
浏览量
30
下载量
9
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010102007558号